- Synkriom and AptaPharma have entered a strategic partnership to support the development, manufacturing, and commercialization of complex pharmaceutical therapies.
- The collaboration combines AptaPharma’s formulation and CDMO capabilities, including its Sugar Lipid Polymer (SLP) platform, with Synkriom’s expertise in consulting, compliance, commercialization, and supply chain governance.
Synkriom and AptaPharma have entered a strategic partnership aimed at accelerating the development, manufacturing, and commercialization of complex pharmaceutical therapies. The collaboration brings together AptaPharma’s formulation development and contract manufacturing capabilities with Synkriom’s expertise in pharmaceutical consulting, commercialization, compliance, and operational governance.
The companies said the partnership will create an integrated pathway from molecule to market. AptaPharma, a U.S.-based CDMO headquartered in Pennsauken, New Jersey, operates an 83,000-square-foot cGMP manufacturing campus focused on complex oral and liquid drug formulations. Its services span concept development, formulation, manufacturing, and commercialization.
AptaPharma’s platform includes its patented Sugar Lipid Polymer (SLP) technology, which is designed to address formulation challenges such as poor solubility, low bioavailability, product instability, and patient tolerability issues. According to the company, the technology supports improved stability, taste masking, and reduced gastrointestinal irritation.
As part of the agreement, Synkriom Chief Executive Officer Komal Dangi has joined AptaPharma as Managing Partner. The companies said the move is intended to strengthen alignment between the organizations and support their focus on pharmaceutical innovation.
Together, Synkriom and AptaPharma will provide services across the product lifecycle, including formulation and development, clinical and commercial manufacturing support, regulatory and compliance readiness, commercialization strategy, supply chain governance, and talent acquisition. The companies said the partnership is intended to help pharmaceutical and life sciences organizations improve operational efficiency, regulatory readiness, manufacturing visibility, and commercialization timelines.
